Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
Vol. 100, No. 5, 2005, pp. 459-465
Bioline Code: oc05114
Full paper language: English
Document type: Research Article
Document available free of charge
Memórias do Instituto Oswaldo Cruz, Vol. 100, No. 5, 2005, pp. 459-465
© Copyright 2005 - Instituto Oswaldo Cruz - Fiocruz.
BCG Moreau Rio de Janeiro - An oral vaccine against tuberculosis - Review|
Thereza Christina Benévolo-de-Andrade; Renata Monteiro-Maia; Catherine Cosgrove & Luiz Roberto R Castello-Branco
The vaccine Bacillus of Calmette Guérin (BCG) was originally developed in France as an oral vaccine against tuberculosis. The oral use of this vaccine was replaced by the parenteral route in almost all countries after the Lubeck disaster. In contrast, Brazil retained the oral delivery of the vaccine until the mid-seventies when it was replaced by the intradermal route. This change in route of delivery was mainly secondary to pressure by medical practitioners based on the poor responses of oral immunized subjects to purified protein derivative (PPD) skin tests. Even after the change of route of delivery, Ataulpho de Paiva Foundation continued making the oral vaccine. Currently, BCG Moreau has been described as one of the most immunogenic and with fewer side effects than other BCGs. The genomics, proteomics and vaccine trials for oral BCG Moreau Rio de Janeiro are currently under investigation. In this review, we intend to describe the history of BCG Moreau Rio de Janeiro in Brazil.
BCG Moreau Rio de Janeiro - oral vaccine - review
Alternative site location: http://memorias.ioc.fiocruz.br